NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.
Read Original Release

Small unpublished study touted by Mount Sinai as evidence software ‘significantly’ reduces major depression

Rating

3 Star

Treating depression w/ software: Tech from Mount Sinai steps into the digital healthcare universe

Our Review Summary

The news release describes an interesting new technology that uses computer technology to try to “rebalance” activity in regions in the brain of depressed patients towards normal patterns by having them repeatedly do a task involving identifying moods on faces. Industry connections were clearly established, which is good. But many details are missing: How many people were in the study? How severe was their depression before and after? What were the limitations? Any adverse events?

 

Why This Matters

We need more and better ways of treating depression, which is one of the chronic diseases that disables millions of U.S. adults. But this release does not go far enough to help readers assess this new therapy’s potential, nor how it might compare to existing techniques such as drugs and psychotherapy.

Criteria

Does the news release adequately discuss the costs of the intervention?

Not Satisfactory

There is no mention of costs. The release would have been stronger if it allowed readers to see the economic context of this new therapy.

Does the news release adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

The release provides only percentages, with no actual numbers for the patients who did and did not receive the therapy. We don’t know if it was 10 patients or 10,000 patients. We also don’t know how the symptoms were measured, nor how severe the depression was in the two groups at baseline and afterward. (We looked up a presentation of the study: It had just 26 people.)

Excerpt: “In the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.”

Also: If the groups received therapy for six weeks, how often did they receive it each week? What was the control group receiving? Was it once for 45 minutes or twice a week for 30 minutes? All these details would help us understand this.

Does the news release adequately explain/quantify the harms of the intervention?

Not Satisfactory

We found just one comment. Excerpt: “The initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.”

Each drug shows different efficacy, so we’re not sure how this was established. Also, it’s standard to track adverse events in trials. For this one, what adverse events did the researchers find? We’re not told.

Does the news release seem to grasp the quality of the evidence?

Not Satisfactory

The news release doesn’t adequately establish the quality of the evidence. Specifically, that because the research has not been published in a journal, it is preliminary. It’s also worth pointing out that six weeks is a short timeframe to measure the effectiveness of a treatment for a chronic disorder.

Does the news release commit disease-mongering?

Satisfactory

There is no disease mongering.

Does the news release identify funding sources & disclose conflicts of interest?

Satisfactory

We were glad to see the for-profit entity, Click Therapeutics, clearly labeled as a contributor to the research and employer of at least one of the investigators.

But we would have liked a clearer explanation of conflicts. Do any of the study authors participate in patents related to this work? How might researchers benefit financially? The study presentation does disclose they hold patent applications.

Excerpt:

“Mount Sinai Innovation Partners (MSIP), the commercialization-arm of the Icahn School of Medicine at Mount Sinai, has been a key partner in this development.”

Does the news release compare the new approach with existing alternatives?

Not Satisfactory

Many other therapies for major depression have been developed, and some of them use technological approaches. Besides these, there are also drugs, psychotherapy and exercise with known benefits. The release would have been stronger if it had listed some of what is already known to work, and explained how the new therapy fit into that context. Is it cheaper? More effective? Easier for rural patients to access?

Does the news release establish the availability of the treatment/test/product/procedure?

Not Applicable

Because the release is about a new therapy, we assume it is not available outside of a clinical study yet.

Does the news release establish the true novelty of the approach?

Satisfactory

The release establishes the novelty about this technology. Although we think this could have waited until a large, randomized study had been completed–and peer-reviewed–before they publicized the work.

Does the news release include unjustifiable, sensational language, including in the quotes of researchers?

Satisfactory

Some of the language appeared to swerve into exaggeration but was not unjustifiable.

Total Score: 4 of 9 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.